HRSA's cease and desist letters to six drug manufacturers likely ensures that this will be another explosive year for 340B contract pharmacy. | Shutterstock

Year 2 of 340B Contract Pharmacy Fight Starts With a Bang

Today is the anniversary of Eli Lilly lighting the fuse on the 340B program’s most explosive year ever.

On May 18, 2020, Lilly sent the U.S. Health Resources and Services Administration (HRSA) a letter saying that, unless it heard otherwise by June 30, it would assume it had HRSA’s blessing to stop offering 340B pricing on Cialis dispensed by covered entities’ contract pharmacies, starting July 1. If an entity didn’t have in-house pharmacy, Lilly said the entity could designate just one contract pharmacy for Cialis shipments.

Today is the anniversary of Eli Lilly lighting the fuse on the 340B program’s most explosive year ever.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report